CA
NZ
UK
AU
IND
US
…
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. " ALS and Frontotemporal Lobar Degeneration; Takeda " Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Sangamo Therapeutics is a clinical-stage genomic medicines company developing zinc-finger-based gene editing, gene therapy and gene regulation approaches for inherited and other serious diseases. Growth may be supported by clinical progress, partnerships and the potential for durable one-time therapies for rare genetic diseases, which may attract investors seeking exposure to novel genomic platforms.
Material risks include clinical and regulatory setbacks, competition from CRISPR and other platforms, high R&D and financing needs, and an uncertain commercialization pathway.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -123.50M | -98.11M | -262.90M | -191.85M | -177.99M |
| Minority interest | - | - | 0.00M | 0.00M | -0.01M |
| Net income | -122.93M | -97.94M | -257.83M | -192.28M | -178.30M |
| Selling general administrative | 34.89M | 44.73M | 61.17M | 62.68M | 63.22M |
| Selling and marketing expenses | - | - | 23.29M | - | - |
| Gross profit | 31.95M | 57.80M | 176.23M | 111.30M | 110.70M |
| Reconciled depreciation | 7.60M | 9.36M | 24.62M | 20.56M | 17.64M |
| Ebit | -123.50M | -98.45M | -118.99M | -221.84M | -200.97M |
| Ebitda | -115.90M | -89.09M | -96.80M | -201.28M | -183.34M |
| Depreciation and amortization | 7.60M | 9.36M | 22.19M | 20.56M | 17.64M |
| Non operating income net other | - | - | - | 9.43M | 5.35M |
| Operating income | -108.00M | -103.97M | -274.00M | -201.28M | -183.34M |
| Other operating expenses | 147.56M | 161.77M | 450.24M | 312.58M | 294.04M |
| Interest expense | - | - | - | -9.43M | 23.00M |
| Tax provision | -0.57M | -0.17M | -4.54M | 0.43M | 0.31M |
| Interest income | 1.30M | 5.86M | 13.29M | 9.43M | 5.35M |
| Net interest income | 1.30M | 5.86M | 13.29M | 9.43M | 5.35M |
| Income tax expense | -0.57M | -0.17M | -5.07M | 0.43M | 0.31M |
| Total revenue | 39.55M | 57.80M | 176.23M | 111.30M | 110.70M |
| Total operating expenses | 139.95M | 161.77M | 450.24M | 312.58M | 294.04M |
| Cost of revenue | 7.60M | 9.36M | 22.19M | - | - |
| Total other income expense net | -15.50M | 5.86M | 11.10M | 9.43M | 5.35M |
| Net income from continuing ops | -122.93M | -97.94M | -249.51M | -192.28M | -178.30M |
| Net income applicable to common shares | - | - | - | -192.28M | -178.29M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 59.74M | 101.64M | 165.32M | 562.51M | 721.92M |
| Intangible assets | - | - | - | 50.73M | 53.76M |
| Other current assets | 4.37M | 5.17M | 12.00M | 18.22M | 15.86M |
| Total liab | 74.01M | 78.86M | 82.43M | 267.55M | 346.58M |
| Total stockholder equity | -14.27M | 22.77M | 82.89M | 294.96M | 375.34M |
| Deferred long term liab | - | - | - | 6.27M | 6.64M |
| Other current liab | 15.29M | 14.38M | 27.88M | 33.39M | 28.39M |
| Common stock | 3.51M | 2.13M | 1.78M | 1.67M | 1.46M |
| Capital stock | 3.51M | 2.13M | 1.78M | 1.67M | 1.46M |
| Retained earnings | -1627.25M | -1504.32M | -1406.38M | -1148.55M | -956.27M |
| Other liab | - | - | - | 116.85M | 174.64M |
| Good will | - | - | 0.00M | 37.55M | 39.70M |
| Other assets | - | - | 0.00M | 18.52M | 16.82M |
| Cash | 20.95M | 41.92M | 45.20M | 100.44M | 178.87M |
| Total current liabilities | 42.47M | 45.80M | 47.73M | 111.71M | 127.89M |
| Current deferred revenue | 0.90M | 7.56M | - | 51.78M | 85.71M |
| Net debt | 5.85M | -11.35M | -7.10M | -57.34M | -130.79M |
| Short term debt | 1.70M | 4.31M | 4.59M | 4.12M | 4.03M |
| Short long term debt total | 26.80M | 30.57M | 38.10M | 43.11M | 48.08M |
| Other stockholder equity | 1610.94M | 1532.49M | 1492.08M | 1450.24M | 1334.14M |
| Property plant equipment | - | - | - | 63.53M | 51.52M |
| Total current assets | 35.83M | 51.69M | 94.33M | 300.33M | 398.77M |
| Long term investments | - | - | 0.00M | 29.84M | 88.17M |
| Net tangible assets | - | - | - | 206.68M | 281.88M |
| Short term investments | - | 0.00M | 35.80M | 177.19M | 197.68M |
| Net receivables | 10.51M | 4.60M | 1.33M | 4.47M | 6.36M |
| Inventory | - | - | - | - | -88.17M |
| Accounts payable | 14.44M | 15.48M | 15.26M | 22.42M | 9.76M |
| Accumulated other comprehensive income | -1.46M | -7.53M | -4.59M | -8.40M | -3.99M |
| Common stock total equity | - | - | - | 1.67M | 1.46M |
| Retained earnings total equity | - | - | - | -1148.55M | -956.27M |
| Non currrent assets other | 9.81M | 13.69M | 16.63M | 12.25M | 10.17M |
| Non current assets total | 23.91M | 49.94M | 70.99M | 262.18M | 323.15M |
| Capital lease obligations | 26.80M | 30.57M | 38.10M | 43.11M | 48.08M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | 37.52M | 158.44M | 79.46M | 271.60M |
| Change to liabilities | - | - | - | 14.28M | -6.08M |
| Total cashflows from investing activities | -0.10M | 37.52M | - | 59.28M | 248.20M |
| Total cash from financing activities | 70.75M | 28.38M | 14.59M | 84.66M | 32.86M |
| Change to operating activities | - | - | - | -6.67M | -9.24M |
| Net income | -122.93M | -97.94M | -257.83M | -192.28M | -178.30M |
| Change in cash | -22.47M | -3.29M | -55.24M | -78.43M | 47.54M |
| Begin period cash flow | 43.42M | 46.70M | 101.94M | 180.37M | 132.83M |
| End period cash flow | 20.95M | 43.42M | 46.70M | 101.94M | 180.37M |
| Total cash from operating activities | -97.21M | -67.14M | -224.84M | -223.63M | -233.25M |
| Issuance of capital stock | 73.67M | 28.99M | 33.73M | 84.87M | 27.10M |
| Depreciation | 7.60M | 9.36M | 22.19M | 20.56M | 17.64M |
| Other cashflows from investing activities | - | 1.95M | - | 79.46M | -0.12M |
| Change to inventory | - | - | - | - | 7.66M |
| Change to account receivables | 0.15M | 0.95M | 3.15M | 2.33M | -0.79M |
| Sale purchase of stock | 0.34M | 0.29M | -1.45M | -2.10M | 3.37M |
| Other cashflows from financing activities | -3.26M | -0.61M | -0.52M | -0.21M | 5.76M |
| Change to netincome | - | - | - | 31.65M | 32.90M |
| Capital expenditures | 0.10M | 0.27M | 21.16M | 20.17M | 23.28M |
| Change receivables | - | - | - | 1.89M | -0.10M |
| Cash flows other operating | - | - | - | -90.03M | -93.96M |
| Cash and cash equivalents changes | - | - | - | -79.68M | 47.81M |
| Change in working capital | -4.22M | 4.51M | -164.03M | -82.32M | -101.89M |
| Stock based compensation | 9.08M | 12.38M | 27.36M | 31.65M | 32.96M |
| Other non cash items | 13.27M | 4.55M | 153.80M | -1.24M | -6.43M |
| Free cash flow | -97.31M | -67.41M | -246.00M | -243.80M | -256.53M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.45 1.12% |
40.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.73 1.03% |
553.15 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. " ALS and Frontotemporal Lobar Degeneration; Takeda " Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | CEO, Pres & Director | 1963 |
| Ms. Prathyusha Duraibabu CPA, M.B.A. | Sr. VP, CFO & Principal Accounting Officer | 1979 |
| Mr. D. Mark McClung | Exec. VP & COO | 1963 |
| Dr. R. Andrew Ramelmeier Ph.D. | Exec. VP of Technical Operations | 1962 |
| Dr. Jason D. Fontenot Ph.D. | Sr. VP & Chief Scientific Officer | 1970 |
| Ms. Aron Feingold | Head of Corp. Communications & Investor Relations Officer | NA |
| Mr. Scott B. Willoughby | Sr. VP, Gen. Counsel & Corp. Sec. | 1975 |
| Ms. Whitney Jones | Sr. VP & Chief People Officer | NA |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Chief Devel. Officer | NA |
| Ms. Heather Erickson | Chief of Staff | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...